Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis
about
Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancerNon-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancerLiquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoringGuide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancerEmerging platforms using liquid biopsy to detect EGFR mutations in lung cancerLiquid biopsy genotyping in lung cancer: ready for clinical utility?Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer.Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapyOptimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer.PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancerPlasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistanceEstimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs.Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).EGFR mutations in lung cancer: from tissue testing to liquid biopsy.Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma.Molecular pathology in real time.Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients.Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.Targeting the EGFR T790M mutation in non-small-cell lung cancer.Integrating liquid biopsies into the management of cancer.Conventional real-time PCR-based detection of T790M using tumor tissue or blood in patients with EGFR TKI-resistant NSCLC.Comparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790 M Mutation Detection in Non-small Cell Lung Cancer after Failure of Tyrosine Kinase Inhibitor Treatment.Resistance mechanisms to drug therapy in breast cancer and other solid tumors: An opinion.Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.Molecular profile of liquid biopsies: next generation biomarkers to improve lung cancer treatment.Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysisThe resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer.Cons: Can liquid biopsy replace tissue biopsy?-the US experience.Rebuttal from Dr. Mino-Kenudson.Can peripheral blood be used as surrogate in detecting epidermal growth factor receptor mutation status in advanced non-small cell lung cancer patients? A meta-analysis.Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients.Circulating DNA in EGFR-mutated lung cancer.Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer.Blood-based biomarkers for precision medicine in lung cancer: precision radiation therapy.Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer.
P2860
Q26775376-7594DD28-0C9B-4B93-9396-A23A40D157DAQ26801357-033BF61F-2AC4-4F59-9D0C-8104AAB3E0C4Q28076191-73926D43-A393-4854-A10C-3FB5F7EB2C22Q28079253-352BB916-3332-4E6F-BDC6-7D7DE0B36121Q28082499-9F6A4A83-3308-4824-A37E-FC36D714EED6Q33567037-F393DA28-F24D-404C-83A1-4E0340D946F9Q33679694-51B9F585-390B-40F2-AED4-F777883E40EBQ33757134-775BF61D-4A59-40EB-BCEC-12EC9DFAEF37Q34515855-751F660F-B348-4CE6-9627-5BB24738E67FQ36095650-0E8271C7-3852-46AC-8C45-52CC826AFA68Q36103228-E2C106FB-7E03-4F2D-A00B-940CBBFC1256Q36574146-229889AC-239D-4A75-9642-449C5493D81CQ36586155-4B039353-74A6-4248-ABEE-1822E8D160FBQ37536958-65CE4180-5355-42F3-B96C-85AE8C9B59E5Q37609221-77BA5855-1A38-4F29-B461-A5216A5CBDE2Q37706578-385C8038-C0B2-4A86-8D84-33B59C17CDE6Q37726138-FEF2A306-8C82-42A7-8E4A-2B5E19863B94Q38515822-863E58CC-0286-4D70-A73B-EBE11AB875B3Q38694431-20129FA8-3A9F-4154-AA3D-98395DE7E1DCQ38756841-1061D627-6234-4592-9192-39F04CE56806Q38844281-7F517959-9C6D-4411-8979-28B38630F6D6Q38845760-F7AF1862-09CD-456E-98D5-A0A9098E8B1CQ38988061-36223028-6ADD-4F27-BFA2-69C5325A8FE5Q39047294-38E75836-9CD2-491C-8131-A6F2A7D92DCEQ39157824-181E3750-EB0C-4CE1-8E41-2B73F538AFBAQ40489387-B6CBCF33-9697-43CC-B725-0CC90325CF2DQ40502030-0A2585D7-0C6C-4779-B7F1-A8CFC4EA15F5Q40989687-78D64DB4-8D6E-42CA-812A-1A8617EAE11EQ41646881-91DE44A1-DDE4-456E-8CFA-29F2A2905B04Q42129522-C37DFC72-E765-4172-B399-C46641E31DFEQ42371507-124185D9-2CCB-4B47-9E30-4A1185F18B7DQ42378535-98B23FBE-9CE1-4EB9-A955-CCFB3F718945Q42398713-E5E07584-DD97-4B34-86C9-AAD41D339B54Q42398715-52AC4855-E580-4913-BBB9-647B43FCDA02Q43172646-C7CC2EFF-A934-4C22-B0D8-BB0023A1D48EQ46246365-442AED05-093D-4D91-9E98-038AC6475B91Q46917029-2615C86D-0A0F-47B9-8CA1-16022A8AC252Q47162466-458DDB40-B128-4F98-9E8E-3FEA4E2D1017Q47344087-FF25FE5E-FB24-46A7-BBD1-78B5C1AF0FE8Q48502619-60FB9C05-2DF9-4915-A5B8-3D5471A718FF
P2860
Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 September 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Diagnostic value of circulatin ...... matic review and meta-analysis
@en
Diagnostic value of circulatin ...... atic review and meta-analysis.
@nl
type
label
Diagnostic value of circulatin ...... matic review and meta-analysis
@en
Diagnostic value of circulatin ...... atic review and meta-analysis.
@nl
prefLabel
Diagnostic value of circulatin ...... matic review and meta-analysis
@en
Diagnostic value of circulatin ...... atic review and meta-analysis.
@nl
P2093
P2860
P31
P921
P356
P1433
P1476
Diagnostic value of circulatin ...... matic review and meta-analysis
@en
P2093
P2860
P2888
P356
10.1038/SREP06269
P407
P5008
P577
2014-09-09T00:00:00Z